Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29868453 | 1.00 | ACHE (0.85) | ACHEBCHE | |
| SCHEMBL5945373 | 1.00 | ACHE (0.85) | ACHEBCHE | |
| SCHEMBL29868444 | 1.00 | ACHE (0.85) | ACHEBCHE | |
| SCHEMBL29869028 | 0.90 | ACHE (0.95) | ACHEBCHE | |
| SCHEMBL1532498 | 0.90 | ACHE (0.95) | ACHEBCHE | |
| SCHEMBL1532467 | 0.88 | ACHE (0.69) | ACHEBCHE | |
| SCHEMBL29868549 | 0.88 | ACHE (0.69) | ACHEBCHE | |
| SCHEMBL24164216 | 0.87 | ACHE (1.00) | ACHEBCHE | |
| SCHEMBL15168191 | 0.87 | ACHE (1.00) | ACHEBCHE | |
| SCHEMBL12059555 | 0.87 | ACHE (1.00) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2533645-B1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2016-07-27 | — | — | EP | disclosed |
| US-20060142323-A1 | Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease | NEUROPHARMA, S.A. (ES) | 2006-06-29 | — | — | US | disclosed |
| EP-1558255-A2 | DUAL BINDING SITE ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Neuropharma, S.A. (ES) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004032929-A2 | DUAL BINDING SITE ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | NEUROPHARMA, S.A. (ES) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142323-A1 | Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease | ACHE, PSEN2, CHAT | ACHE 1/4885BCHE 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.